SURMOUNT-5, the first randomized head-to-head trial directly comparing the two medications, found tirzepatide produced significantly greater weight loss than semaglutide at 72 weeks: 20.2% average body weight reduction vs 13.7%, with nearly twice as many participants reaching the ≥25% weight loss threshold (31.6% vs 16.1%). Tirzepatide's advantage comes from activating an additional hormone receptor (GIP) alongside GLP-1. Semaglutide remains a well-validated, highly effective option — a 13.7% average reduction is a clinically meaningful outcome — and may still be the better fit depending on cost, side-effect tolerance, and individual clinical factors.
Both medications belong to the same broad drug class — they mimic gut hormones released after eating that regulate appetite and blood sugar — but they don't target the same receptors, and that difference explains the gap in the SURMOUNT-5 results.
The GIP receptor's role in fat cells is the piece that's new relative to semaglutide: GIP appears to influence how fat tissue takes up and stores lipids, and when that pathway is activated alongside GLP-1, the combination seems to produce a bigger effect on fat mobilization than either pathway alone. This is the leading explanation for why tirzepatide consistently outperforms semaglutide across both the earlier separate trials and now the direct head-to-head comparison.
Published in NEJM in 2025, SURMOUNT-5 enrolled 751 adults with obesity (without type 2 diabetes) and randomized them to either tirzepatide (maximum tolerated dose of 10mg or 15mg) or semaglutide 2.4mg for 72 weeks — the first time these two medications had been compared directly in the same trial rather than inferred from separate studies in different populations.
Notably, tirzepatide's advantage held consistent across subgroups — sex, age, baseline BMI, and presence of metabolic comorbidities all showed the same directional result. It's also worth stating plainly: both medications produced clinically meaningful weight loss. A 13.7% reduction is a significant, health-improving outcome by any standard obesity-treatment benchmark — semaglutide isn't a "losing" option, it's simply outperformed by tirzepatide's dual mechanism in this comparison.
Both medications share a class-wide gastrointestinal side effect profile, most pronounced during dose escalation and typically improving after 4–8 weeks at a stable dose.
| Side effect | Tirzepatide | Semaglutide |
|---|---|---|
| Nausea | ~40% (dose-escalation phase) | ~44% |
| Diarrhea | ~23% | ~30% |
| Vomiting | ~13% | ~24% |
| Constipation | ~18% | ~24% |
| Discontinuation due to GI effects | 2.7% | 5.6% |
Interestingly, the SURMOUNT-5 head-to-head data showed slightly lower GI-related discontinuation with tirzepatide despite its greater efficacy — suggesting the dual mechanism isn't achieving its larger effect at the cost of meaningfully worse tolerability. Both medications carry a boxed warning regarding thyroid C-cell tumors based on rodent data (not established in humans) and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Serious adverse events, including pancreatitis, are rare with both.
| Option | Monthly cost | Notes |
|---|---|---|
| Wegovy (brand semaglutide) | ~$1,350/mo | Obesity indication; insurance coverage varies widely |
| Zepbound (brand tirzepatide) | ~$1,060–$1,350/mo | Obesity indication; manufacturer savings card available |
| ★ Luma Health tirzepatide | $297/mo flat | Compounded, VialsRX TX#35264, all doses |
| ★ Luma Health semaglutide | $197/mo flat | Compounded, VialsRX TX#35264, all doses |
For patients without insurance coverage for either brand-name option, compounded pricing is the more financially realistic path to either medication. The $100/mo price gap between Luma's semaglutide and tirzepatide roughly tracks the underlying efficacy difference — but if cost is the deciding factor for you, semaglutide's 13.7% average outcome is still clinically meaningful, and $197/mo flat may be the more sustainable long-term choice than stretching for tirzepatide and risking discontinuation over cost.
Switching between these medications is common, particularly for patients who plateau on semaglutide or want to pursue greater weight loss after establishing tolerability on a GLP-1 medication.
If you're switching through Luma Health, there's no separate re-enrollment fee — your prescription simply moves to tirzepatide's $297/mo flat rate starting with your next cycle. For a deeper walkthrough of the inadequate-response criteria that typically prompt this switch, see our full guide on when to switch GLP-1 medications.
Luma Health prescribes both compounded semaglutide ($197/mo flat) and tirzepatide ($297/mo flat), with VialsRX (TX Board #35264) preparing both. No separate consultation fee to choose either.
Start With Luma Health →Based on the SURMOUNT-5 head-to-head trial, tirzepatide produces greater average weight loss — 20.2% vs 13.7% at 72 weeks — and nearly twice as many participants reached the ≥25% weight loss threshold. This is now the first direct comparative evidence rather than an inference from separate trials. That said, both medications produce clinically meaningful results, and individual response varies based on adherence, dose, diet, and metabolic factors.
Semaglutide activates only GLP-1 receptors, which regulate appetite, gastric emptying, and insulin secretion. Tirzepatide activates both GLP-1 and GIP receptors simultaneously. The additional GIP pathway appears to affect fat tissue metabolism directly, producing an additive effect on satiety and weight loss beyond what GLP-1 activation alone achieves.
Brand-name Zepbound (tirzepatide) runs approximately $1,060–$1,350/month without insurance; brand-name Wegovy (semaglutide) runs approximately $1,350/month. Compounded versions are significantly less expensive — Luma Health prescribes compounded tirzepatide at $297/mo flat and compounded semaglutide at $197/mo flat, both prepared by VialsRX (TX Board #35264).
SURMOUNT-5 was the first randomized, head-to-head trial directly comparing tirzepatide and semaglutide in the same population — 751 adults with obesity but without type 2 diabetes, over 72 weeks. Tirzepatide produced 20.2% mean weight loss vs 13.7% for semaglutide, a meaningful relative improvement. More tirzepatide participants also reached the ≥25% weight loss threshold (31.6% vs 16.1%), and tirzepatide showed a numerically lower rate of GI-related treatment discontinuation.
Both share a similar gastrointestinal side effect profile — nausea, vomiting, diarrhea, and constipation are most common during dose escalation. In the SURMOUNT-5 data, semaglutide showed somewhat higher rates of vomiting, diarrhea, and constipation, along with a higher GI-related discontinuation rate (5.6% vs 2.7% for tirzepatide). Individual tolerability varies, and some patients find one medication easier to tolerate than the other regardless of these population-level averages.
Yes. No washout period is required — the switch can be made directly. Clinical guidance generally recommends starting tirzepatide at 2.5mg regardless of your prior semaglutide dose, to minimize GI side effects during the transition, then following the standard titration schedule from there. Discuss the specifics with your prescribing clinician.
Yes, for many patients. A 13.7% average weight loss is a clinically significant, health-improving outcome, and semaglutide has the added benefit of SELECT trial evidence supporting cardiovascular risk reduction in patients with established cardiovascular disease. Semaglutide is also the less expensive option at $197/mo flat through Luma Health, and lower cost is directly linked to better long-term treatment continuity — a medication you can afford to stay on consistently often outperforms a more potent one you can't sustain.